Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Acknowledgement to reviewers98
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells74
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms57
Refining long-term surveillance requirements in patients with differentiated thyroid cancer57
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression53
Celebrating the 80th anniversary of hormone ablation for prostate cancer50
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs41
Acknowledgement to reviewers41
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients40
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas39
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing38
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications38
Targeting growth hormone in cancer: future perspectives31
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas30
Prognostic of recurrence and survival in poorly differentiated thyroid cancer30
Update on the genetics of paragangliomas30
Metabolically active brown adipose tissue in PPGL: an observational cohort study29
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts29
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet28
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation28
Radioiodine treatment: an historical and future perspective27
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells26
Peptide receptor radionuclide therapy in malignant insulinoma25
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation25
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells25
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer24
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours24
Whole-exome sequencing of rectal neuroendocrine tumors22
Therapy considerations in neuroendocrine prostate cancer: what next?22
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells22
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma22
Antitumor immune response is associated with favorable survival in GEP-NEN G322
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly21
Gender-affirming care and endocrine-related cancers21
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis21
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen20
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring20
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective20
Effect of TSH levels during active surveillance of PTMC according to age19
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction19
Immunotherapy for endocrine tumours: a clinician’s perspective18
From bench to bedside in the sella: translational developments in pituitary tumour genetics17
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis17
Exploring stem cell biology in pituitary tumors and derived organoids16
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study15
Steroid profile in patients with breast cancer and in mice treated with mifepristone15
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms15
ThyroidPrint®: clinical utility for indeterminate thyroid cytology14
Acknowledgement to reviewers14
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors14
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer14
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study13
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review13
Inhibition of GATA2 in prostate cancer by a clinically available small molecule13
New therapeutic opportunities for women with low-grade serous ovarian cancer13
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma13
Acknowledgement to reviewers13
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management12
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity12
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice12
Cancer in Ecuadorian subjects with Laron syndrome (ELS)12
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer12
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus12
In vivo and in vitro analysis of functional effects of the SDHD H50R variant12
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms11
Deiodinases in thyroid tumorigenesis11
Beyond the three P’s: adrenal involvement in MEN111
Genetic disorders and insulinoma/glucagonoma11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma11
Sexual dimorphism in thyroid cancer: evidence from preclinical studies11
Non-pituitary GH regulation of the tissue microenvironment11
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal11
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland11
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid11
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort11
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma11
In memoriam: Charis Eng MD PhD (1962–2024)10
Genetic variants and down-regulation of CACNA1H in pheochromocytoma10
MicroRNAs as regulators of tumor metabolism10
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer10
Surrogate molecular classification of LAR breast cancer in routine workflow10
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane10
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L210
Mendelian randomization to investigate the link between TSH and thyroid cancer10
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes10
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis10
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer10
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover9
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors9
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading9
Precocious puberty due to intracranial germ cell tumors: a case–control study9
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center9
Management of high-grade neuroendocrine neoplasms: impact of functional imaging9
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer9
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma9
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis9
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms9
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer9
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors9
0.049149036407471